Vontobel Holding Ltd. Sells 71,336 Shares of Moderna, Inc. (NASDAQ:MRNA)

Vontobel Holding Ltd. cut its stake in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 32.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,516 shares of the company’s stock after selling 71,336 shares during the quarter. Vontobel Holding Ltd.’s holdings in Moderna were worth $17,916,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Theleme Partners LLP raised its position in shares of Moderna by 0.3% in the second quarter. Theleme Partners LLP now owns 6,354,406 shares of the company’s stock valued at $907,727,000 after purchasing an additional 17,466 shares during the period. Renaissance Technologies LLC increased its position in Moderna by 108.2% during the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after acquiring an additional 1,984,458 shares during the period. Northern Trust Corp increased its position in Moderna by 0.6% during the first quarter. Northern Trust Corp now owns 3,503,325 shares of the company’s stock worth $603,483,000 after acquiring an additional 20,416 shares during the period. Price T Rowe Associates Inc. MD increased its position in Moderna by 40.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,392,374 shares of the company’s stock worth $484,601,000 after acquiring an additional 973,933 shares during the period. Finally, Banque Pictet & Cie SA increased its position in Moderna by 0.9% during the second quarter. Banque Pictet & Cie SA now owns 3,026,346 shares of the company’s stock worth $432,314,000 after acquiring an additional 26,863 shares during the period. 63.11% of the stock is owned by institutional investors.

Moderna Trading Down 0.1 %

Shares of Moderna stock opened at $196.76 on Wednesday. The firm’s 50-day moving average price is $185.97 and its two-hundred day moving average price is $161.27. Moderna, Inc. has a 12-month low of $115.03 and a 12-month high of $217.25. The company has a quick ratio of 1.80, a current ratio of 2.10 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $75.59 billion, a price-to-earnings ratio of 7.12 and a beta of 1.71.

Moderna (NASDAQ:MRNA – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $2.53 earnings per share for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). Moderna had a net margin of 55.00% and a return on equity of 70.03%. The company had revenue of $3.36 billion during the quarter, compared to analyst estimates of $3.33 billion. On average, analysts forecast that Moderna, Inc. will post 21.31 earnings per share for the current fiscal year.

Insider Activity

In other news, President Stephen Hoge sold 1,085 shares of the firm’s stock in a transaction that occurred on Tuesday, November 29th. The shares were sold at an average price of $173.80, for a total value of $188,573.00. Following the sale, the president now directly owns 1,627,416 shares in the company, valued at approximately $282,844,900.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, President Stephen Hoge sold 1,085 shares of Moderna stock in a transaction that occurred on Tuesday, November 29th. The shares were sold at an average price of $173.80, for a total transaction of $188,573.00. Following the sale, the president now directly owns 1,627,416 shares in the company, valued at approximately $282,844,900.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, November 3rd. The stock was sold at an average price of $147.10, for a total transaction of $5,884,000.00. Following the sale, the chief executive officer now owns 5,411,946 shares in the company, valued at $796,097,256.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 445,899 shares of company stock worth $80,212,386. Corporate insiders own 17.30% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of recent research reports. JPMorgan Chase & Co. lowered their price target on shares of Moderna from $165.00 to $122.00 and set a “neutral” rating on the stock in a research report on Monday, October 24th. Piper Sandler raised their price target on shares of Moderna from $214.00 to $217.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 20th. Morgan Stanley lowered their price target on shares of Moderna from $209.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Chardan Capital raised their price target on shares of Moderna from $191.00 to $208.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 18th. Finally, The Goldman Sachs Group increased their price objective on shares of Moderna from $290.00 to $296.00 and gave the stock a “buy” rating in a research note on Thursday, October 13th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Moderna has an average rating of “Moderate Buy” and a consensus price target of $192.00.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.